{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:59:36Z","timestamp":1782979176151,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00296-019-04241-8","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T13:33:46Z","timestamp":1548336826000},"page":"561-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Infliximab-associated focal segmental glomerulosclerosis in a patient with ankylosing spondylitis"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-790X","authenticated-orcid":false,"given":"Handan","family":"Yarkan Tu\u011fsal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7417-4682","authenticated-orcid":false,"given":"Berrin","family":"Zengin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-1369","authenticated-orcid":false,"given":"G\u00f6k\u00e7e","family":"Kenar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8347-0873","authenticated-orcid":false,"given":"Ger\u00e7ek","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-7594","authenticated-orcid":false,"given":"Mehtat","family":"\u00dcnl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-2622","authenticated-orcid":false,"given":"Fato\u015f","family":"\u00d6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-9307","authenticated-orcid":false,"given":"Merih","family":"Birlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"4241_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2017.11.003","volume":"50","author":"M Samson","year":"2018","unstructured":"Samson M, Espigol-Frigole G, Terrades-Garcia N, Prieto-Gonzalez S, Corbera-Bellalta M, Alba-Rovira R, Hernandez-Rodriguez J, Audia S, Bonnotte B, Cid MC (2018) Biological treatments in giant cell arteritis & Takayasu arteritis. Eur J Intern Med 50:12\u201319. \n                    https:\/\/doi.org\/10.1016\/j.ejim.2017.11.003","journal-title":"Eur J Intern Med"},{"issue":"6","key":"4241_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MD.0b013e318190f170","volume":"87","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ, Group BS (2008) A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87(6):345\u2013364. \n                    https:\/\/doi.org\/10.1097\/MD.0b013e318190f170","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"4241_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","volume":"22","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22(5):847\u2013861. \n                    https:\/\/doi.org\/10.1016\/j.berh.2008.09.008","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"4241_CR4","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00296-012-2624-9","volume":"33","author":"SH Lee","year":"2013","unstructured":"Lee SH, Lee EJ, Chung SW, Song R, Moon JY, Lee SH, Lim SJ, Lee YA, Hong SJ, Yang HI (2013) Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int 33(7):1689\u20131692. \n                    https:\/\/doi.org\/10.1007\/s00296-012-2624-9","journal-title":"Rheumatol Int"},{"issue":"6","key":"4241_CR5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/BF01451293","volume":"17","author":"ES Strobel","year":"1998","unstructured":"Strobel ES, Fritschka E (1998) Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 17(6):524\u2013530","journal-title":"Clin Rheumatol"},{"issue":"5","key":"4241_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/rheumatology\/26.5.341","volume":"26","author":"DW Jones","year":"1987","unstructured":"Jones DW, Mansell MA, Samuell CT, Isenberg DA (1987) Renal abnormalities in ankylosing spondylitis. Br J Rheumatol 26(5):341\u2013345","journal-title":"Br J Rheumatol"},{"issue":"5","key":"4241_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5414\/CN109262","volume":"89","author":"D Leonard","year":"2018","unstructured":"Leonard D, Cortese C, Wadei HM, Porter Ii IE, Aslam N (2018) Behcet\u2019s syndrome and focal segmental glomerulosclerosis with nephrotic syndrome - successful treatment with etanercept. Clin Nephrol 89(5):371\u2013375. \n                    https:\/\/doi.org\/10.5414\/CN109262","journal-title":"Clin Nephrol"},{"issue":"2","key":"4241_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.15403\/jgld.2014.1121.242.infx","volume":"24","author":"G Dumitrescu","year":"2015","unstructured":"Dumitrescu G, Dahan K, Treton X, Corcos O, Bouhnik Y, Stefanescu C (2015) Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis. J Gastrointestin Liver Dis 24(2):249\u2013251. \n                    https:\/\/doi.org\/10.15403\/jgld.2014.1121.242.infx","journal-title":"J Gastrointestin Liver Dis"},{"issue":"11","key":"4241_CR9","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1093\/ndt\/gfp314","volume":"24","author":"A Jacquet","year":"2009","unstructured":"Jacquet A, Francois H, Frangie C, Yahiaoui Y, Ferlicot S, Micelli C, Mariette X, Durrbach A (2009) IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. Nephrol Dial Transplant 24(11):3540\u20133542. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfp314","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"4241_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.5414\/CNP70240","volume":"70","author":"T Hatakeyama","year":"2008","unstructured":"Hatakeyama T, Komatsuda A, Matsuda A, Togashi M, Maki N, Masai R, Sawada K, Wakui H (2008) Renal amyloidosis associated with extracapillary glomerulonephritis and vasculitis in a patient with inflammatory bowel disease treated with infliximab. Clin Nephrol 70(3):240\u2013244","journal-title":"Clin Nephrol"},{"issue":"3","key":"4241_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5527\/wjn.v2.i3.90","volume":"2","author":"C Lemaitre","year":"2013","unstructured":"Lemaitre C, Iwanicki-Caron I, Vecchi CD, Bertiaux-Vandaele N, Savoye G (2013) Acute renal artery occlusion following infliximab infusion. World J Nephrol 2(3):90\u201393. \n                    https:\/\/doi.org\/10.5527\/wjn.v2.i3.90","journal-title":"World J Nephrol"},{"issue":"10","key":"4241_CR12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2169\/internalmedicine.55.5834","volume":"55","author":"M Ota","year":"2016","unstructured":"Ota M, Iwai H, Imai K, Kamiya M, Yoshihashi-Nakazato Y, Miyasaka N, Kohsaka H (2016) Acute Tubulointerstitial Nephritis Associated with Infliximab in a Patient with Crohn\u2019s Disease. Intern Med 55(10):1367\u20131370. \n                    https:\/\/doi.org\/10.2169\/internalmedicine.55.5834","journal-title":"Intern Med"},{"issue":"5","key":"4241_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4166\/kjg.2014.63.5.308","volume":"63","author":"YJ Yoo","year":"2014","unstructured":"Yoo YJ, Chung SY, Gu DH, Ko GJ, Pyo HJ, Kwon YJ, Bak YT, Won NH (2014) A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn\u2019s disease. Korean J Gastroenterol 63(5):308\u2013312","journal-title":"Korean J Gastroenterol"},{"issue":"12","key":"4241_CR14","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1093\/ndt\/gfi180","volume":"20","author":"G Chin","year":"2005","unstructured":"Chin G, Luxton G, Harvey JM (2005) Infliximab and nephrotic syndrome. Nephrol Dial Transplant 20(12):2824\u20132826. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfi180","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"4241_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1620\/tjem.245.149","volume":"245","author":"T Sato","year":"2018","unstructured":"Sato T, Kawasaki Y, Ito A, Izumi H, Kawamorita N, Yamashita S, Mitsuzuka K, Matsuura T, Watanabe M, Arai Y (2018) Infliximab-Induced Tubulointerstitial Nephritis with Image Findings of Striated Nephrogram in Crohn\u2019s Disease. Tohoku J Exp Med 245(3):149\u2013152. \n                    https:\/\/doi.org\/10.1620\/tjem.245.149","journal-title":"Tohoku J Exp Med"},{"issue":"8","key":"4241_CR16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","volume":"13","author":"M Piga","year":"2014","unstructured":"Piga M, Chessa E, Ibba V, Mura V, Floris A, Cauli A, Mathieu A (2014) Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev 13(8):873\u2013879. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2014.05.005","journal-title":"Autoimmun Rev"},{"issue":"3","key":"4241_CR17","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/ijd.12622","volume":"54","author":"N Kluger","year":"2015","unstructured":"Kluger N, Du-Thanh A, Bessis D, Servel MF, Mourad G (2015) Psoriasis-associated IgA nephropathy under infliximab therapy. Int J Dermatol 54(3):e79\u2013e80. \n                    https:\/\/doi.org\/10.1111\/ijd.12622","journal-title":"Int J Dermatol"},{"issue":"6","key":"4241_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12328-009-0112-x","volume":"2","author":"Y Ueno","year":"2009","unstructured":"Ueno Y, Tanaka S, Onitake T, Hanaoka R, Yoshioka K, Ito M, Chayama K (2009) Infliximab treatment for Crohn\u2019s disease in a patient with IgA nephropathy. Clin J Gastroenterol 2(6):380\u2013383. \n                    https:\/\/doi.org\/10.1007\/s12328-009-0112-x","journal-title":"Clin J Gastroenterol"},{"issue":"7","key":"4241_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nrrheum.2011.35","volume":"7","author":"JC Prinz","year":"2011","unstructured":"Prinz JC (2011) Autoimmune-like syndromes during TNF blockade: does infection have a role? Nat Rev Rheumatol 7(7):429\u2013434. \n                    https:\/\/doi.org\/10.1038\/nrrheum.2011.35","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"4241_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1046\/j.1523-1755.2002.00172.x","volume":"61","author":"ET McCarthy","year":"2002","unstructured":"McCarthy ET, Sharma M (2002) Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum. Kidney Int 61(2):534\u2013541. \n                    https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00172.x","journal-title":"Kidney Int"},{"issue":"3","key":"4241_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000167463","volume":"7","author":"J Laurent","year":"1987","unstructured":"Laurent J, Belghiti D, Bruneau C, Lagrue G (1987) Diclofenac, a nonsteroidal anti-inflammatory drug, decreases proteinuria in some glomerular diseases: a controlled study. Am J Nephrol 7(3):198\u2013202. \n                    https:\/\/doi.org\/10.1159\/000167463","journal-title":"Am J Nephrol"},{"issue":"12","key":"4241_CR22","first-page":"400","volume":"68","author":"L Vogt","year":"2010","unstructured":"Vogt L, Laverman GD, Navis G (2010) Time for a comeback of NSAIDs in proteinuric chronic kidney disease? Neth J Med 68(12):400\u2013407","journal-title":"Neth J Med"},{"issue":"5","key":"4241_CR23","doi-asserted-by":"publisher","first-page":"e37957","DOI":"10.1371\/journal.pone.0037957","volume":"7","author":"MH Borst de","year":"2012","unstructured":"de Borst MH, Nauta FL, Vogt L, Laverman GD, Gansevoort RT, Navis G (2012) Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysis. PLoS One 7(5):e37957. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0037957","journal-title":"PLoS One"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04241-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04241-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04241-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T19:08:09Z","timestamp":1579720089000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04241-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4241"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04241-8","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"17 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient gave a written informed consent before written.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}